Transgenomic, Inc. (NASDAQ:
TBIO) is a global biotechnology company advancing personalized medicine in
cardiology, oncology and inherited diseases through progressive diagnostic
technologies, such as its revolutionary ICE-COLD PCR™ (MX-ICP). Through this technology,
the company provides more sensitive and accurate mutation detection without
major costs or impact to current processes.
In May, Transgenomic built on
the versatility of its MX-ICP platform through the launch of a novel epidermal
growth factor receptor (EGFR) CLIA test for mutation detection in cancer
patients, effectively opening the door for more informed diagnoses, better
treatment decisions and ongoing patient monitoring moving forward. The first
tests using this platform were for the detection of EGFR T790M mutations, which
have been linked to patient resistance of current non-small cell lung cancer
(NSCLC) treatment options.
“Launching our multiplexed ICE
COLD-PCR-based CLIA mutation detection service for oncologists and their
patients is a major milestone for Transgenomic and, we believe, an important
advance for the field of precision medicine,” Paul Kinnon, president and chief
executive officer of Transgenomic, stated in a news release. “The unsurpassed
accuracy of MX-ICP and its ability to produce highly sensitive and accurate
results from small amounts of almost any type of patient sample, especially
liquid biopsies, allows broad use.”
MX-ICP has been shown effective
in the detection of mutation with a range of biofluid samples – including
blood, plasma, serum, urine, sputum and bronchial lavage – allowing for highly
accurate, non-invasive diagnostics of all known and unknown mutations.
In recent months, Transgenomic
has leveraged the considerable market for its diagnostic technologies and
clinical and research services to record improved financial results. During the
first quarter of 2015, the company’s net sales were recorded at a 4 percent
year-over-year increase, with laboratory services sales increasing by over 30
percent for the same period.
“The company made good progress
in the first quarter in strengthening our historical businesses while preparing
for the imminent launch of our breakthrough technology: Multiplexed ICE-COLD
PCR™,” continued Kinnon. “We achieved a double digit percentage increase in
overall net sales excluding the divested Surveyor product line, including a
robust 32 percent increase in the critical laboratory services segment.”
Moving forward, look for
Transgenomic to continue building on its recent progress in order to maximize
industry growth. For prospective investors, continued industry adoption of the
company’s MX-ICP technology could provide ample opportunity to realize
sustainable returns in the years to come.
For more information, visit
www.transgenomic.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
